- Fresenius Medical (NYSE: FMS) exceeded analyst expectations with strong quarterly earnings and revenue.
- Analysts maintain a positive outlook, with a price target suggesting potential upside for the healthcare stock.
- The company demonstrates stable financial health, supported by key valuation and solvency ratios.
Fresenius Medical (NYSE: FMS) is a global healthcare company that provides products and services for individuals with chronic kidney failure. As a leading provider of specialized dialysis care, Fresenius Medical operates a network of clinics and manufactures dialysis equipment. The company faces competition from other major healthcare providers in the competitive renal care market.
On August 3, 2026, Fresenius Medical announced strong quarterly financial results. The company reported earnings per share of $0.66, which was higher than the analyst consensus estimate of $0.62. This key metric highlights the company’s profitability per share.
Fresenius Medical also posted revenue of $5.60 billion, surpassing the estimated $5.48 billion for the quarter. Following the report, Truist Financial adjusted its price target on Fresenius Medical to $25.00 from $26.00, as highlighted by TheFly. This new target still represents a potential 6% upside from its price at the time.
For investors analyzing stock valuation, Fresenius Medical has a trailing price-to-earnings (P/E) ratio of 12.61. This ratio helps investors gauge the stock’s value relative to its past earnings. The company’s price-to-sales ratio is 0.57, comparing its stock price to its revenues. Fresenius Medical also shows an earnings yield of approximately 8.3%.
The company’s financial health and stability appear strong. It maintains a debt-to-equity ratio of 0.83, which measures its debt relative to shareholder equity. Fresenius Medical also has a current ratio of 1.20. This indicates it has $1.20 in short-term assets for every $1.00 of short-term liabilities, demonstrating a solid ability to cover immediate financial obligations.
